Publications by authors named "Giorgio Milazzo"

17Publications

Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma.

Oncotarget 2018 07 6;9(52):30024. Epub 2018 Jul 6.

Division of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.

View Article and Find Full Text PDF
July 2018

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma.

Oncotarget 2018 04 17;9(29):20323-20338. Epub 2018 Apr 17.

Division of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.

View Article and Find Full Text PDF
April 2018

MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma.

Biochim Biophys Acta Gene Regul Mech 2018 Mar 3;1861(3):235-245. Epub 2018 Feb 3.

Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy; Health Sciences and Technology - Interdepartmental Center for Industrial Research (HST-ICIR), University of Bologna, Ozzano Emilia, Italy. Electronic address:

View Article and Find Full Text PDF
March 2018

Letting the breaks off MYCN.

Cell Death Differ 2016 12 14;23(12):1904-1905. Epub 2016 Oct 14.

Cancer Research, Department of Cell Biology, Murdoch Children's Research Institute, Royal Children's Hospital, Flemington Road, Melbourne, Victoria 3052, Australia.

View Article and Find Full Text PDF
December 2016

SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma.

Cancer Lett 2015 Jul 2;363(1):37-45. Epub 2015 Apr 2.

Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne NE2 4HH, UK. Electronic address:

View Article and Find Full Text PDF
July 2015

Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression.

J Natl Cancer Inst 2014 Jul 6;106(7). Epub 2014 Jun 6.

Affiliations of authors: Children's Cancer Institute Australia for Medical Research, Randwick NSW, Australia (PYL, GMM, AET, MW, BL, BBC, MK, TL); Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy (DE, GM, GP); Kids Cancer Centre, Sydney Children's Hospital, Randwick NSW, Australia (GMM); Department of Pathology and Inflammation and Infection Research Centre, University of New South Wales, Kensington 2052, Australia (PP); Institute of Molecular Medicine, Martin Luther University, ZAMED, Halle, Germany (JLB, SH); School of Medicine and Public Health, Priority Research Centre for Cancer Research, University of Newcastle, Callaghan NSW, Australia (XDZ); Harry Perkins Institute of Medical Research, Centre for Medical Research, University of Western Australia, Nedlands WA, Australia (AF); Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical Research, Darlinghurst NSW, Australia (AS); St Vincent's Clinical School, University of New South Wales, Darlinghurst NSW, Australia (AS, JSM, MED); Australian Centre for Nanomedicine, Randwick NSW, Australia (MK); Garvan Institute of Medical Research, Darlinghurst NSW, Australia (AS, JSM, MED); School of Women's & Children's Health, University of New South Wales, Randwick NSW, Australia (TL).

View Article and Find Full Text PDF
July 2014